RxNorm 1597588

Lynparza

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 1597588 unique identifier include: Lynparza (6820148).

RxNorm Atom ID: 6820148 - Brand Name
Lynparza

RXCUI:
1597588 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
6820148 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Lynparza - Description of concept identifier
Term Type (TTY):
BN - Term type in source with name and description
Term Type Name:
Brand Name - Name of term type in source
Term Type Description:
A proprietary name for a family of products containing a specific active ingredient. - Description of term type in source
Code:
1597588 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 6820148 Attributes

PropertyValueExplanation
RXN BN CARDINALITYsingleCardinality of RxNorm Brand Name Atom

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Olaparib


Olaparib tablets are used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib tablets are also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. Olaparib tablets are also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib tablets and capsules are also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.